Table 1.
Description of the study cohort.
IBS |
||||
---|---|---|---|---|
Healthy controls | IBS | IBS-C | IBS-D | |
N | 25 | 36 | 15 | 21 |
Caucasian (n, %) | 24 (96) | 36 (100) | 15 (100) | 21 (100) |
Gender (n, % female) | 23 (92) | 33 (92) | 15 (100) | 15 (86) |
Age (mean ± SEM) | 39 ± 2 | 42 ± 2 | 47 ± 3 | 39 ± 3 |
(range) | (18 – 60) | (22 – 73) | (27 – 73) | (22 – 64) |
BMI (mean ± SEM) | 26.1 ± 1.2 | 27.4 ± 1 | 25.5 ± 1.5 | 28.8 ± 1.3 |
(range) | (18.3 – 40.2) | (20 – 42.6) | (20.0 – 42.6) | (20.9 – 41.8) |
Concurrent treatment | ||||
SSRI | n=2 | n=10 | n=2 | n=8 |
SNRI | - | n=1 | n=1 | - |
DA | - | n=3 | n=2 | n=1 |
TCA | - | n=2 | n=1 | n=1 |
SSRI: selective serotonin reuptake inhibitor; SNRI: serotonin and norepinephrine reuptake inhibitor; DA: dopaminergic agent (bupropion); TCA: tricyclic antidepressant